ARTICLE | Clinical News
Ipatasertib: Phase II data
May 23, 2016 7:00 AM UTC
A double-blind, placebo-controlled, international Phase II trial in 253 patients with metastatic CRPC previously treated with docetaxel showed that once-daily 400 mg oral ipatasertib plus Zytiga abir...